Progress towards a new targeted treatment approach that will provide personalised medicine, rather than providing the same first line treatment for conditions, will amass more patient data than ever before. Being able to handle and store this data, whilst ensuring it is readily available for other healthcare organisations, is essential.
Additionally, with the cost of drug development rising and existing drugs coming off patent at an alarming rate, high-performing pharmaceutical firms are focusing on data-driven approaches to dramatically improve efficiencies across manufacturing, distribution and markets, while gaining better insight to drive improved decision making. It is estimated that such efficiencies could save the industry as much as $90bn.
With sales fast increasing and Pharmaceutical organisations looking at new forms of marketing and customer retention, it is clear that a new solution is required to ensure compliance, security and the ability to implement a data-driven approach. Cloud environments can underpin the deployment of the digital technologies you need to support transformation, for example combatting existing issues surrounding drug prescriptions by pharmaceutical organisations and patients’ subsequent concerns around who has accessed their records. Similarly this could also enable pharmaceutical companies to develop a deeper insight and understanding of the NHS.
UKCloud Health offers a cost-effective cloud platform that represents genuine value-for-money, even when compared with global cloud platforms.
$92bn worth of name-brand drugs will come off patent in the next five years. In an industry already challenged by over-capacity, there will be greater emphasis than ever on manufacturing efficiency.
From component sourcing and resource planning to capacity planning and production a data-driven approach to improving efficiency is essential to retaining competitive advantage.
87% of prescription drug sales were handled by distributors in 2010, a 6% increase over 2007.
Shortening the supply chain and generating greater efficiencies from closer integration and collaboration present not only a great challenge, but also an enormous opportunity.
In the last year alone the top 3 pharmaceutical giants incurred $7bn in additional costs settling fines for illegal marketing.
A new data-driven approach is required to improve targeting, avoid infringements and improve overall efficiency.